Original articlePhase I and pharmacokineticsEORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer
Phase I and pharmacokinetics
Under an Elsevier user license
open archive
Keywords
breast cancer
liposomal doxorubicin
schedule
Cited by (0)
Copyright © 2002 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.